INBIOGEN Statistics

Total Valuation

INBIOGEN has a market cap or net worth of KRW 126.11 billion. The enterprise value is 121.29 billion.

Market Cap	126.11B
Enterprise Value	121.29B

Important Dates

The next estimated earnings date is Wednesday, May 14, 2025.

Earnings Date	May 14, 2025
Ex-Dividend Date	n/a

Share Statistics

INBIOGEN has 9.98 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	9.98M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.02%
Owned by Institutions (%)	0.00%
Float	2.06M

Valuation Ratios

The trailing PE ratio is 7.82.

PE Ratio	7.82
Forward PE	n/a
PS Ratio	17.91
PB Ratio	0.79
P/TBV Ratio	0.79
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.35, with an EV/FCF ratio of -1,033.02.

EV / Earnings	7.52
EV / Sales	17.23
EV / EBITDA	7.35
EV / EBIT	7.85
EV / FCF	-1,033.02

Financial Position

The company has a current ratio of 4.38, with a Debt / Equity ratio of 0.01.

Current Ratio	4.38
Quick Ratio	4.32
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-7.62
Interest Coverage	-118.53

Financial Efficiency

Return on equity (ROE) is 10.64% and return on invested capital (ROIC) is -2.50%.

Return on Equity (ROE)	10.64%
Return on Assets (ROA)	-2.47%
Return on Invested Capital (ROIC)	-2.50%
Return on Capital Employed (ROCE)	-3.79%
Revenue Per Employee	171.73M
Profits Per Employee	393.23M
Employee Count	41
Asset Turnover	0.05
Inventory Turnover	12.99

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	1.16
52-Week Price Change	n/a
50-Day Moving Average	7,442.60
200-Day Moving Average	n/a
Relative Strength Index (RSI)	76.45
Average Volume (20 Days)	177,014

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, INBIOGEN had revenue of KRW 7.04 billion and earned 16.12 billion in profits.

Revenue	7.04B
Gross Profit	628.51M
Operating Income	-6.09B
Pretax Income	16.12B
Net Income	16.12B
EBITDA	-5.03B
EBIT	-6.09B
Earnings Per Share (EPS)	n/a

Full Income Statement

Balance Sheet

The company has 5.72 billion in cash and 894.79 million in debt, giving a net cash position of 4.82 billion or 482.88 per share.

Cash & Cash Equivalents	5.72B
Total Debt	894.79M
Net Cash	4.82B
Net Cash Per Share	482.88
Equity (Book Value)	159.84B
Book Value Per Share	n/a
Working Capital	7.16B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -33.13 million and capital expenditures -84.28 million, giving a free cash flow of -117.41 million.

Operating Cash Flow	-33.13M
Capital Expenditures	-84.28M
Free Cash Flow	-117.41M
FCF Per Share	-11.76

Full Cash Flow Statement

Margins

Gross margin is 8.93%, with operating and profit margins of -86.45% and 228.98%.

Gross Margin	8.93%
Operating Margin	-86.45%
Pretax Margin	228.98%
Profit Margin	228.98%
EBITDA Margin	-71.43%
EBIT Margin	-86.45%
FCF Margin	n/a

Dividends & Yields

INBIOGEN does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	12.78%
FCF Yield	-0.09%

Stock Splits

The last stock split was on September 21, 2023. It was a reverse split with a ratio of 0.05.

Last Split Date	Sep 21, 2023
Split Type	Reverse
Split Ratio	0.05

Scores

INBIOGEN has an Altman Z-Score of 0.15. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.15
Piotroski F-Score	n/a